Trial
NCT05177718
Natalizumab and Chronic Inflammation
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Vanderbilt University Medical Center
Collaborators
Biogen
Condition
Multiple Sclerosis
Intervention
Natalizumab 300 MG in 15 ML Injection
Why stopped
Sponsor declined further support
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-18